Open Nav

Please submit your session questions in advance at

American Gene Technologies

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its patented, lead candidate for an HIV cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Four key patents in AGT’s novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.

  • Date:Monday, February 11
  • Time:2:00 PM - 2:15 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23271
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Share the progress in broad gene and cell therapy applications at AGT.
  • Company
  • Company HQ City:Rockville
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$26,000,000
  • Size of Last Investment Round:$15,000,000
  • CEO/Top Company Official:Jeff Galvin
  • Year Founded:2008
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development:HIV cure - autologous cell therapy
  • Development Phase of Primary Product:NDA Preparation / In Review
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
Jeff Galvin
American Gene Technologies